Evidence map›Paper›PMID 28298655›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2017

Dual NEP/ECE inhibition improves endothelial function in mesenteric resistance arteries of 32-week-old SHR.

Pieter Lemkens, Leon Ja Spijkers, Merlijn J Meens, Jelly Nelissen, Ben Janssen, Stephan Lm Peters, Paul Mh Schiffers, Jo Gr De Mey

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Pieter LemkensDepartment of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
Leon Ja SpijkersDepartment of Pharmacology and Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands.
Merlijn J MeensDepartment of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
Jelly NelissenDepartment of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
Ben JanssenDepartment of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
Stephan Lm PetersDepartment of Pharmacology and Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands.
Paul Mh SchiffersDepartment of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
Jo Gr De MeyDepartment of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
Maastricht University · NLAcademic Medical Center · NLUniversity of Geneva · CHUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelin 1 (ET-1), a potent vasoconstrictor, pro-mitogenic and pro-inflammatory peptide, may promote development of endothelial dysfunction and arterial remodeling. ET-1 can be formed through cleavage of big-ET-1 by endothelin-converting enzyme (ECE) or neutral endopeptidase (NEP). We investigated whether chronic treatment with the novel dual NEP/ECE inhibitor SOL1 improves functional and structural properties of resistance-sized arteries of 32-week-old male spontaneously hypertensive rats (SHR). SHR received a chronic 4-week treatment with SOL1, losartan or hydralazine. We then compared effects of inhibition of NO synthase (NOS) (100 μM l-NAME), blockade of ET

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsBenzazepinesBosentanEndothelin-Converting EnzymesEndothelium, VascularEnzyme InhibitorsHydralazineHypertensionLosartanMesenteric ArteriesMuscle ContractionNeprilysinNG-Nitroarginine Methyl EsterNitric Oxide Synthase Type IIIProtease Inhibitors2-((1-(((1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)amino)carbonyl)cyclopentyl)methyl)-4-((3-(methylamino)propyl)(methyl)amino)-4-oxobutanoic acidAngiotensin II Type 1 Receptor BlockersBenzazepinesBosentanEndothelin-Converting EnzymesEnzyme InhibitorsHydralazineLosartanNeprilysinNG-Nitroarginine Methyl EsterNitric Oxide Synthase Type IIIProtease InhibitorsSulfonamides

Identifiers

PMID28298655
OpenAlexW2596521374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.